Jaa Roberson
Human Resources Officer at DAY ONE BIOPHARMACEUTICALS, INC.
Jaa Roberson active positions
| Companies | Position | Start | End |
|---|---|---|---|
| DAY ONE BIOPHARMACEUTICALS, INC. | Human Resources Officer | 2021-09-12 | - |
Career history of Jaa Roberson
Former positions of Jaa Roberson
| Companies | Position | Start | End |
|---|---|---|---|
| BELLICUM PHARMACEUTICALS, INC. | Human Resources Officer | 2018-04-30 | 2020-10-31 |
| ACHAOGEN | Human Resources Officer | - | - |
Training of Jaa Roberson
| Rice University | Undergraduate Degree |
| San Francisco Conservatory of Music | Graduate Degree |
Statistics
International
| United States | 6 |
Operational
| Human Resources Officer | 3 |
| Undergraduate Degree | 1 |
| Graduate Degree | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| DAY ONE BIOPHARMACEUTICALS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Bellicum Pharmaceuticals, Inc.
 Bellicum Pharmaceuticals, Inc. BiotechnologyHealth Technology Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX. | Health Technology |
Achaogen, Inc.
 Achaogen, Inc. Pharmaceuticals: MajorHealth Technology Achaogen, Inc. engages in developing and commercializing innovative antibacterial agents for multi-drug resistant gram-negative infections. The firm is also involved in the development of C-Scape, an orally administered antibiotic to address a serious unmet need for an effective oral treatment for patients with complicated urinary tract infections, including pyelonephritis caused by extended spectrum beta-lactamases producing Enterobacteriaceae. The company was founded by Nathaniel Eames David, Floyd E. Romesberg, and Peter G. Schultz in June 2002 and is headquartered in South San Francisco, CA. | Health Technology |
- Stock Market
- Insiders
- Jaa Roberson
- Experience